Fig. 1

The impact of recombinant human proteoglycan 4 (rhPRG4) treatment on cytosolic and nuclear levels of nuclear factor kappa B (NFκB) p50 subunit in Prg4 ^+/+ and Prg4 ^-/- synoviocytes; *p < 0.001, **p < 0.01, ***p < 0.05. a Representative western blot showing cytosolic and nuclear p50 protein in Prg4 ^+/+ and Prg4 ^-/- synoviocytes in control, CD44 antibody (CD44 Ab)-treated, CD44 Ab + rhPRG4-treated and rhPRG4-treated cells. Lamin B1 was used as a nuclear loading control and β-Actin was used as a cytosolic loading control. b Semi-quantitative densitometry analysis of normalized cytosolic p50 protein in untreated and rhPRG4-treated Prg4 ^+/+ and Prg4 ^-/- synoviocytes. Prg4 ^-/- synoviocytes had higher cytosolic p50 compared to Prg4 ^+/+ synoviocytes. rhPRG4 (100 μg/ml) reduced cytosolic p50 levels in Prg4 ^+/+ and Prg4 ^-/- synoviocytes. Co-incubation with CD44 Ab (1.25 μg/ml) did not alter the effect of rhPRG4. Data are presented as mean ± standard deviation of three independent experiments. c Semi-quantitative densitometry analysis of normalized nuclear p50 protein in untreated and rhPRG4-treated Prg4 ^+/+ and Prg4 ^-/- synoviocytes. Prg4 ^-/- synoviocytes had higher nuclear p50 compared to Prg4 ^+/+ synoviocytes. rhPRG4 (100 μg/ml) reduced nuclear p50 levels in Prg4 ^+/+ and Prg4 ^-/- synoviocytes. Co-incubation with CD44 Ab (1.25 μg/ml) did not alter the effect of rhPRG4. Data are presented as mean ± standard deviation of three independent experiments